<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Norfloxacin (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Norfloxacin (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Norfloxacin (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="10916" href="/d/html/10916.html" rel="external">see "Norfloxacin (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52867725"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ALTI-Norfloxacin;</li>
<li>APO-Norfloxacin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F202604"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Fluoroquinolone</li></ul></div>
<div class="block doa drugH1Div" id="F202563"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="119e325a-ec37-4012-a93c-94e7ae8a8fc7">Gonorrhea, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gonorrhea, uncomplicated:</b>
<b>Oral:</b> 800 mg as a single dose.<b> Note:</b> Norfloxacin is not a preferred therapy for gonorrhea due to resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-PHAC.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-PHAC.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a0ae1fc5-2f2e-4d8b-98f2-20932ab0eea9">Spontaneous bacterial peritonitis, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spontaneous bacterial peritonitis, prophylaxis (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For secondary prophylaxis in patients with prior spontaneous bacterial peritonitis (SBP) and primary prophylaxis in patients at high risk for SBP (eg, low ascites protein [&lt;1.5 g/dL] with advanced liver failure or impaired kidney function). Some experts also use for prophylaxis during hospitalization in patients with cirrhosis and either acute GI bleeding or ascites protein &lt;1 g/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-17030175','lexi-content-ref-Runyon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-17030175','lexi-content-ref-Runyon.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 400 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29653741','lexi-content-ref-17854593','lexi-content-ref-Runyon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29653741','lexi-content-ref-17854593','lexi-content-ref-Runyon.1'])">Ref</a></span>). For patients with cirrhosis and acute GI bleeding, some experts use 400 mg twice daily following, or as an alternative to parenteral prophylaxis, for a total antibiotic duration of 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Runyon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Runyon.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystitis, acute uncomplicated or acute simple cystitis (infection limited to the bladder without signs/symptoms of upper tract, prostate, or systemic infection) (alternative agent):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Use is discouraged due to safety concerns and increasing resistance; reserve for those who have no alternative treatment options (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26926640','lexi-content-ref-FDA.1','lexi-content-ref-Hooton.2021b','lexi-content-ref-Hooton.2021a','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26926640','lexi-content-ref-FDA.1','lexi-content-ref-Hooton.2021b','lexi-content-ref-Hooton.2021a','lexi-content-ref-21292654'])">Ref</a></span>). However, for men who have severe symptoms or there is concern for early prostate involvement, some experts prefer fluoroquinolones (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021b'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 400 mg twice daily for 3 days (females) or 5 days (males) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021b','lexi-content-ref-Hooton.2021a','lexi-content-ref-1316075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021b','lexi-content-ref-Hooton.2021a','lexi-content-ref-1316075'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urinary tract infection, complicated (including pyelonephritis): </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>If the prevalence of fluoroquinolone resistance is &gt;10%, an initial dose of a long-acting parenteral antimicrobial (eg, ceftriaxone) followed by oral therapy is recommended for outpatients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021c','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021c','lexi-content-ref-21292654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 400 mg twice daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021c','lexi-content-ref-1441044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021c','lexi-content-ref-1441044'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991793"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≤30 mL/minute/1.73 m<sup>2</sup>: 400 mg once daily.</p></div>
<div class="block doha drugH1Div" id="F50988990"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F202564"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F202525"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (1%), headache (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased lactate dehydrogenase</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, diarrhea, dyspepsia, flatulence, heartburn, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic and oncologic: Decreased hematocrit, eosinophilia, leukopenia, neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams, anxiety, depression, disorientation, drowsiness, euphoria, hallucination, insomnia, irritability, mood changes, nervousness, paresthesia, personality disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, tendinopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Epiphora, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia, hypoglycemia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, delirium, disturbance in attention, idiopathic intracranial hypertension, increased intracranial pressure, memory impairment, nightmares, paranoid ideation, peripheral neuropathy, restlessness, suicidal ideation, suicidal tendencies, toxic psychosis</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Rupture of tendon, tremor</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, exfoliative dermatitis, localized erythema (periorbital), skin photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i> colitis, constipation, pancreatitis (rare), xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vulvovaginal candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia (sometimes associated with G6PD deficiency), hemophthalmos, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia, confusion, dysarthria, dysphasia, fatigue, Guillain-Barré syndrome, hypertonia, polyneuropathy, psychotic reaction, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis, asthenia, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, eye irritation, eye pain, nystagmus disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss (transient), tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis, renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F202539"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to norfloxacin, quinolones, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F202522"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered cardiac conduction: Fluoroquinolones may prolong QTc interval; avoid use in patients with a history of QTc prolongation, uncorrected hypokalemia, hypomagnesemia, or concurrent administration of other medications known to prolong the QT interval (including Class Ia and Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, and tricyclic antidepressants).</p>
<p style="text-indent:-2em;margin-left:4em;">• Aortic aneurysm and dissection: Fluoroquinolones have been associated with aortic aneurysm ruptures or dissection within 2 months following use, particularly in elderly patients. Fluoroquinolones should not be used in patients with a known history of aortic aneurysm or those at increased risk, including patients with peripheral atherosclerotic vascular diseases, hypertension, genetic disorders involving blood vessel changes (eg, Marfan syndrome, Ehlers-Danlos syndrome), and elderly patients, unless no other treatment options are available. Longer treatment duration (eg, &gt;14 days) may increase risk (Lee 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Glucose regulation: Fluoroquinolones have been associated with the development of serious, and sometimes fatal, hypoglycemia. These events have occurred most often in elderly patients with diabetes, but have also been reported in patients without a prior history of diabetes. Prompt identification and treatment of hypoglycemia is essential. Individual quinolones may differ in their potential to cause this effect. It was most evident with gatifloxacin (no longer marketed as s systemic formulation). Hyperglycemia has also been associated with the use of fluoroquinolones. Patients should be monitored closely for signs/symptoms of disordered glucose regulation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.</p>
<p style="text-indent:-2em;margin-left:4em;">• Phototoxicity: Avoid excessive sunlight and take precautions to limit exposure (eg, loose fitting clothing, sunscreen); may cause moderate-to-severe phototoxicity reactions. Discontinue use if photosensitivity occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Serious adverse reactions: <b>[Canadian Boxed Warning]: Fluoroquinolones are associated with disabling and potentially irreversible serious adverse reactions that may occur together, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects.</b> Discontinue norfloxacin immediately and avoid use of fluoroquinolones in patients who experience any of these serious adverse reactions. Patients of any age or without pre-existing risk factors have experienced these reactions; may occur within hours to weeks after initiation.</p>
<p style="text-indent:-2em;margin-left:6em;">- CNS effects: Fluoroquinolones have been associated with an increased risk of CNS effects including seizures, increased intracranial pressure (including pseudotumor cerebri), and toxic psychosis; may also cause nervousness, agitation, insomnia, anxiety, nightmares, paranoia, dizziness, confusion, tremors, hallucinations, depression, and suicidal thoughts or actions. May occur following the first dose; discontinue immediately and avoid further use of fluoroquinolones in patients who experience these reactions. Use with caution in patients with known or suspected CNS disorder, or risk factors that may predispose to seizures or lower the seizure threshold.</p>
<p style="text-indent:-2em;margin-left:6em;">- Peripheral neuropathy: Fluoroquinolones have been associated with an increased risk of peripheral neuropathy; may occur soon after initiation of therapy and may be irreversible; discontinue if symptoms of sensory or sensorimotor neuropathy occur. Avoid use in patients who have previously experienced peripheral neuropathy.</p>
<p style="text-indent:-2em;margin-left:6em;">- Tendinitis/tendon rupture: Fluoroquinolones have been associated with an increased risk of tendonitis and tendon rupture in all ages; risk may be increased with concurrent corticosteroids, solid organ transplant recipients, and in patients &gt;60 years of age, but has also occurred in patients without these risk factors. Rupture of the Achilles tendon has been reported most frequently; but other tendon sites (eg, rotator cuff, biceps, hand) have also been reported. Inflammation and rupture may occur bilaterally. Cases have been reported within hours or days of initiation, and up to several months after discontinuation of therapy. Strenuous physical activity, renal failure, and previous tendon disorders may be independent risk factor for tendon rupture. Discontinue at first sign of tendon pain, swelling, inflammation or rupture. Avoid use in patients with a history of tendon disorders or who have experienced tendinitis or tendon rupture.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: May exacerbate muscle weakness related to myasthenia gravis; avoid use in patients with known history of myasthenia gravis. Cases of severe exacerbations, including the need for ventilatory support and deaths, have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use caution with renal impairment; dose adjustment required. May increase risk of tendon rupture.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may increase risk of tendon rupture.</p>
<p style="text-indent:-2em;margin-left:4em;">• Syphilis: Since norfloxacin is ineffective in the treatment of syphilis and may mask symptoms, all patients should be tested for syphilis at the time of gonorrheal diagnosis and 3 months later.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Adverse effects (eg, tendon rupture, QT changes) may be increased in the elderly.</p>
<p style="text-indent:-2em;margin-left:4em;">• G6PD deficiency: Hemolytic reactions may (rarely) occur with fluoroquinolone use in patients with G6PD deficiency (Luzzatto 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Safety and efficacy have not been established in children; other quinolones have caused transient arthropathy in children.</p></div>
<div class="block prod-avail drugH1Div" id="F29245365"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the United States.</p></div>
<div class="block geq drugH1Div" id="F56836829"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F202541"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Noroxin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (20): $96.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867726"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 400 mg</p></div>
<div class="block adm drugH1Div" id="F202536"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Hold antacids, sucralfate, or multivitamins/supplements containing iron, zinc, magnesium, or aluminum for at least 2 hours before or after giving norfloxacin; do not administer together. Administer on an empty stomach with water (at least 1 hour before or 2 hours after meals, milk, or other dairy products).</p></div>
<div class="block use drugH1Div" id="F202535"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">Uncomplicated and complicated urinary tract infections (UTIs) caused by susceptible gram-negative and gram-positive bacteria; sexually transmitted disease (eg, uncomplicated urethral and cervical gonorrhea) caused by <i>N. gonorrhoeae.</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Norfloxacin is not a preferred therapy for gonorrhea due to resistance (CDC [Workowski 2021]; PHAC 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Because fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions (eg, tendinitis and tendon rupture, peripheral neuropathy, CNS effects), reserve norfloxacin for use in patients who have no alternative treatment options for acute uncomplicated UTIs.</p></div>
<div class="block off-label drugH1Div" id="F25469460"><span class="drugH1">Use: Off-Label: Adult</span><p>Spontaneous bacterial peritonitis, prophylaxis</p></div>
<div class="block mst drugH1Div" id="F202611"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Norfloxacin may be confused with Norflex, Noroxin [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;">Noroxin [DSC] may be confused with Neurontin, Norflex</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F202599"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F202527"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Quinolones may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the cardiotoxic effect of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the absorption of Quinolones. Of concern only with oral administration of quinolones. Management: Avoid concurrent administration of quinolones and antacids to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone; see full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caffeine and Caffeine Containing Products: Norfloxacin may increase the serum concentration of Caffeine and Caffeine Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May decrease the absorption of Quinolones. Of concern only with oral administration of both agents. Management: Consider administering an oral quinolone at least 2 hours before or 6 hours after the dose of oral calcium to minimize this interaction. Monitor for decreased therapeutic effects of quinolones during coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Norfloxacin may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delamanid: Quinolones may enhance the QTc-prolonging effect of Delamanid.  Management: Avoid concomitant use if possible. If coadministration is unavoidable, frequent monitoring of electrocardiograms (ECGs) throughout the full delamanid treatment period should occur.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Didanosine: Quinolones may decrease the serum concentration of Didanosine. Didanosine may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant). Management: Avoid use of fexinidazole with OAT1/3 substrates when possible. If combined, monitor for increased OAT1/3 substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Preparations: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for enox-, levo-, nor-, oflox-, peflox, or nalidixic acid) oral iron.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: May decrease the serum concentration of Quinolones. Management: Administer oral quinolone antibiotics at least one hour before or four hours after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Levoketoconazole.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Salts: May decrease the serum concentration of Quinolones. Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar/enox-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe/enox-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May enhance the cardiotoxic effect of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolones. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Administer oral quinolones at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (ie, calcium, iron, magnesium, selenium, zinc). Monitor for decreased quinolone efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Quinolones. Specifically, minerals in the multivitamin/mineral product may impair absorption of quinolone antibiotics. Management: Administer oral quinolones at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (ie, calcium, iron, magnesium, selenium, zinc). Monitor for decreased therapeutic effects of quinolones.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Quinolones may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadifloxacin: May enhance the adverse/toxic effect of Quinolones.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitisinone: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrofurantoin: May diminish the therapeutic effect of Norfloxacin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: May decrease the absorption of Quinolones. Management: Give oral quinolones at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May decrease the excretion of Quinolones. Specifically, probenecid may decreased the renal excretion of quinolone antibiotics. Probenecid may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Strontium Ranelate: May decrease the serum concentration of Quinolones. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: May decrease the serum concentration of Quinolones. Management: Avoid concurrent administration of quinolones and sucralfate to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Norfloxacin may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaborbactam: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Quinolones may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zinc Salts: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for enox-, levo-, nor-, pe- or ofloxacin or nalidixic acid) oral zinc salts.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F202554"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Norfloxacin average peak serum concentrations may be decreased if taken with food or dairy products. Management: Administer on an empty stomach with water at least 1 hour before or 2 hours after meals, milk, or other dairy products.</p></div>
<div class="block pri drugH1Div" id="F202542"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Norfloxacin crosses the placenta, distributing to cord blood and amniotic fluid (Wise 1984). Based on available data, an increased risk of teratogenic effects has not been observed following norfloxacin use during pregnancy (Bar-Oz 2009; Padberg 2014).</p></div>
<div class="block brc drugH1Div" id="F202543"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Norfloxacin was not detected in the milk of breastfeeding mothers administered an oral 200 mg dose. It is not known if concentrations would be detectable after a higher dose or multiple doses. Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends caution be used if administered to a breastfeeding patient.</p></div>
<div class="block dic drugH1Div" id="F202544"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Oral formulations should be administered on an empty stomach with water (at least 1 hour before or 2 hours after meals, milk, or other dairy products). Maintain fluid intake to ensure adequate hydration and urinary output.</p></div>
<div class="block mop drugH1Div" id="F15577086"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor CBC, renal and hepatic function periodically if therapy is prolonged.</p></div>
<div class="block pha drugH1Div" id="F202521"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Norfloxacin is a DNA gyrase inhibitor. DNA gyrase is an essential bacterial enzyme that maintains the superhelical structure of DNA. DNA gyrase is required for DNA replication and transcription, DNA repair, recombination, and transposition; bactericidal</p></div>
<div class="block phk drugH1Div" id="F202538"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapid, up to 40%</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 10% to 15%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 3 to 4 hours; Renal impairment (CrCl ≤30 mL/minute): 6.5 hours; Elderly: 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (26% to 32% as unchanged drug; 5% to 8% as metabolites); feces (30%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F202545"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Noracin | Noroxin | Spectrama | Urobacid | Uroxin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Actobian | Bio tarbun | Fada norfloxacina | Floxamicin | Floxatral | Frifloxacina | Memento nf | Norflol | Norfloxacina | Norfloxacina ahimsa | Norfloxacina craveri | Norfloxacina fabra | Norfloxacina klonal | Norfloxacina Lba | Norfloxacina northia | Norfloxacina vannier | Noroxin | Norsol | Parcetin | Ritromine | Uro-linfol | Urofos | Uronovag | Uroseptal | Urotem | Uroxacin | Wenflox</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Floxacin | Norfloxacin sandoz | Zoroxin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo-norfloxacin | Cm norfloxacin | Insensye | Norflohexal | Norfloxacin an | Norfloxacin sandoz | Noroxin | Nufloxib | Roxin | Tw norfloxacin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Floxin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Docnorfloxa | Norfloxacin ratiopharm | Norfloxacine eg | Norfloxacine eurogenerics | Norfloxacine Sandoz | Norfloxacine teva generics belgium | Zoroxin</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Norfen | Norfloxacine tm | Norfloxine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Nolicin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Androfloxin | Flox | Floxacin | Floxamox | Floxatom | Floxatrat | Floxilin | Floximed | Floxin | Floxinol | Genosept | Neofloxin | Noracin | Norf | Norflamin | Norfloxacino | Norfloxan | Norfloxasan | Norfloxil | Norfloxmed | Norflurin | Norxacin | Norxin | Ocinoflox | Quinoform | Respexil | Uniao norfloxacino | Uritrat | Uroflox | Uroplex | Uroseptal | Urotrobel | Uroxazol-n</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Norflocin | Norfloxacin Adico | Norfloxacin hp | Noroxin | Norsol</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Norfloxacine tm</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Fulgram | Noroxin | Urekolin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Jin ya jie</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ambigram | Flox | Floxfar | Fuxacilin | Nefrixine | Noflanil | Noprose | Noraflox | Norbact | Norbagram | Norflomed | Norfloquin | Norfloxacina | Norfloxacina MK | Norfloxacino | Norigran | Uralgic | Urigen | Uriseptan | Urocyclar | Urotrin | Yeloz | Zoroxin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Gyrablock | Nolicin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bactracid | Barazan | Firin | Norflohexal | Norflosal | Norflox | Norflox 1 a pharma | Norfloxacin 1 a pharma | Norfloxacin al | Norfloxacin ratiopharm | Norfloxbeta | Norfluxx | Zoroxin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ambigram | Floxacin | Noracina | Noractin | Norfloxacina | Norfloxacino | Noroxin | Norulox | Orsanac | Uroctal | Urofloxin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Norflogen | Norfloxacina | Norfloxacina MK | Norfloxacino | Noroxin | Orsanac | Urobacid | Uroflox | Uroseptal</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Nolicin | Norfloxacin ratiopharm</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Epinor | Neofloxin | Noracin | Norbactin | Normash | Noroxin | Spectrama</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Baccidal | Esclebin | Espeden | Nalion | Norflok | Norfloxacina inkey | Norfloxacino Acost | Norfloxacino bayvi | Norfloxacino bexal | Norfloxacino Cinfa | Norfloxacino normon | Norfloxacino pensa | Norfloxacino qualix | Norfloxacino Ranbaxy | Noroxin | Uroctal | Vicnas | Xasmun</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Gyrablock | Norcin | Nortop | Trizolin | Uriflox</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lexinor | Norfloxacin ratiopharm | Norfloxacin sandoz</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Norfloxacine arrow | Norfloxacine biogaran | Norfloxacine eg | Norfloxacine gnr | Norfloxacine irex | Norfloxacine ivax | Norfloxacine merck | Norfloxacine Qualimed | Norfloxacine Ratiopharm | Norfloxacine Sandoz | Norfloxacine teva | Norfloxacine Wint | Noroxine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Utinor</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Alenbit | Constilax | Fluseminal | Grenis | Norfloxacina | Norocin | Ovinol | Pistofil | Setanol | Sinobid | Sofasin | Urisold | Urobacid | Urospes n | Vetamol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Euroxacin | Floxen | Lexinor | Surflox | Uroctal</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Noflox | Nolicin | Trizolin uro</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Nolicin | Nolicin s | Norfloxacin ratiopharm | Norfloxacin-k</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Lexinor | Norbactin | Noryx | Pyrflox | Urobacid | Wianor</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Apirol</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alflox | Anquin | Bacigyl | Biofloxin | Emflox | Enflox | Enteroflox | Entoflox | Flox | Flox lark | Floxacret | Floxilet | Floxin | Heliflox | Inor | Klib | Loxone | Markflox | Mediflox | Meriflox | N-200 | N-400 | N.r.flox | Nefrotab | Negaflox | Nitdin | Nor-u | Noraxin | Norbactin | Norbid | Norflot | Norflox | Norfloxain | Nori | Norilet | Norlup | Norly | Normax | Nornij | Norrit | Norspan | Norstar | Nortas | Nortee | Norzole | Osoflox | Quinobid | Quinolox | Quinotz | R-flox | Synor | Tamflox | Tyzon | Uriben | Urinor | Uroflox | Uronor | Ut-flox | Utibid | Worflox | Zeflox | Zyflox</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Diperflox | Norflox | Norfloxacina | Norfloxacina eg | Noroxin | Renoxacin | Sebercim | Uticina | Utinor</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Noracin | Norax | Noroxin | Urobacid</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Asudufe | Baccidal | Baccidal torii | Bafurokisaru | Barocul | Basteen | Blemalart | Blemalart choseido | Mitatonin mita | Nofloxan | Nofxan | Norbaccin | Norbacdal | Norcozine | Norfloxacin emec | Noruzist | Notler | Shinun | Stbanil | Towakisan | Unasera | Xaflor</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Asnor | Carenorfcin | Floxinor | Floxinox | Mediflox | Negaflox | Niflox | Noflox | Norfen | Norflogen | Norflopin | Norflox | Norilet | Norlab | Normax | Normed | Norzole | Surflox | Uniflox | Uriflox</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Baccidal | Bameron | Barotam | Effectsal | Floxa | Furactam | Gramitin | Hanlim norfloxacin | Moaloxin | Neutam | Newsadal | Norfloxacin tab. 400mg huons | Norfo | Noritacin | Norocan | Noroxin | Olmaricin | Proking | Urecacin | Urekacin | Urisco | Urobid | Uroxacin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Noroxin | Uroctal | Uroxin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Noroxin | Urobacid | Uroctal | Uroxin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Drobacid | Negaflox | Nolicin | Norbactinum | Norfloxum | Urobacid</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Norfloxacine eg | Zoroxin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Negaflox | Nolicin | Norbactinum | Norflok | Norfloxacin ratiopharm | Norfloxum | Urobacin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Noracin | Noroxine | Urobacid | Uroctal</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Axoflanol | Difoxacil | Floxacin | Microxin | Noflorox | Norfloxacina | Noroxin | Norquinol | Oranor</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Effectsal | Floxen | Janacin | Lexinor | Nolicin | Nor | Norbactin | Norflok | Norfloxin | Norfox | Norgan | Pharmaniaga Norfloxacin | Rexacin | Tomexin | Trizolin | Urinox | Urobacid | Utibid</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Norbactin | Norfen</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Norfloxacine | Norfloxacine actavis | Norfloxacine Ratiopharm | Norocin | Noroxin | Noroxine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Norflohexal</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Noroxin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ampliron | Grenis | N-flox | Norbactin | Norbiotic | Norflolip | Norfloxacina | Norfloxacino | Norilet | Noroxin | Uroflox | Uroquin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ellatracid | Euroflox | Flamorel | Flornox | Heiwin | Jaydisyn | Lexiflox | Lexinor | M-flox | Norbactin | Norex | Nortram | Pharmawealth norfloxacin | Septinor | Urinox | Urobacid | Winaflox</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Alenbit | Bacnor | Bactinor | Floxa | Floxanor | Floxin | Helinox | Isflox | Nefrolon | Newsadal | Nicaflex | Nicoflox | Nolicin | Norfax | Norfin | Norflox | Norilet | Norocin | Noroxin | Norsept | Nortic | Novoflox | Noxacin | Qunor | Trizolin | Unique | Uracin | Urid | Uriflox | Uritac | Uroquin | Utibex | Utinor | Webnor</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Nolicin | Norbactin | Norsept</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Noroxin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Norfloxacina | Noroxin | Taflox | Uroflox</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Flomed | Nipron | Nogrixim | Norfloxacino genfar | Norfloxina | Orsanac | Uridon</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Gyrablock | Noracin | Norax | Noroxin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Epinor | Fluseminal | Nolicin | Norfloxacina atb | Urospes n | Utibid</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Anquin | Gyrablock | Locsone | Loxon | Negaflox | Nolicin | Norbactin | Norbactinum | Norfacin | Norfloxum | Norilet | Normax | Renor | Utibid</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Noracin | Noroxin | Uroxin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Lexinor | Norfloxacin AstraZeneca | Norfloxacin krka | Norfloxacin meda | Norfloxacin sandoz | Norfloxacin stada</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Bexinor | Effectsal | Foxgoria | Gyrablock | Lexinor | Loxone | Nolicin | Norbactin | Urobacid</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Nolicin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Gyrablock | Nolicin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">B g b norflox | Benor | Canflox | Cannorflox | Cenor | Cofoxin | Crossa | Duocin | Farnoxin | Floxa | Floxenor | Floximed | Fornacin f | Foxgoria | Foxin | Foxinon | Gonorcin | Gyrablock | J.V.Flox | Janacin | Kressflox | Lexfor | Lexiflox | Leximed | Lexinor | Loxone | M-flox | Manoflox | Medic-nor | Myfloxin | N-floxa | Noflox | Nogo | Nomed | Noracin | Noraxin | Norbactin | Norcin | Norcoxa | Norfa | Norfan | Norfass | Norfcin | Norflacil | Norflo | Norflocin | Norflox Osoth | Norfloxcin | Norfloxil | Norfloxin | Norfloxno | Norfloxpac | Norfloxstar | Norfloxyl | Norfox | Norfoxcin | Norgo | Norgoria | Normed | Norraxin | Norsa | Norsep | Norspec | Norxacin | Norxia | Norxibid | Norxin | Noxcin | Noxinor | Oxacin | Paioxin | Pinflox | Proxinor | Sanorflox | Sefnor | Snoffocin | Tc noxin | Troxacin | U-Flox | Urinox | Uritracin | Vesxacin | Vifloxacin | Xacin | Zinor</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Noracin | Noroxine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Noroxin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Baccidal | Baxicin | Flocidal | N.F.S | Noraxin | Norflodal | Noxacin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Negaflox | Nolicin | Norbactinum | Norfloxum | Norilet | Normax | Sofasin | Synflox</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agonor | Asnor</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ectalin | Floxuri | Uronor | Uroxacina</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Danilon | Norbactin | Norflosan | Norfloval | Norfloxacina | Norfloxacino | Norilet | Noroxin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Floxin | Norfloxacin Actor | Noroxin | Utifloxa | Utin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Anquin | Floxilet | Norfen | Normax | Quinolox | Renor | Uroflox</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Norfloxin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33067334">
<a name="33067334"></a>Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. <i>Gut</i>. 2021;70(1):9-29. doi:10.1136/gutjnl-2020-321790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/33067334/pubmed" id="33067334" target="_blank">33067334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19181435">
<a name="19181435"></a>Bar-Oz B, Moretti ME, Boskovic R, O'Brien L, Koren G. The safety of quinolones--a meta-analysis of pregnancy outcomes. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2009;143(2):75-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/19181435/pubmed" id="19181435" target="_blank">19181435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26926640">
<a name="26926640"></a>Bidell MR, Palchak M, Mohr J, Lodise TP. Fluoroquinolone and third-generation-cephalosporin resistance among hospitalized patients with urinary tract infections due to Escherichia coli: do rates vary by hospital characteristics and geographic region? <i>Antimicrob Agents Chemother</i>. 2016;60(5):3170-3173. doi:10.1128/AAC.02505-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/26926640/pubmed" id="26926640" target="_blank">26926640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29653741">
<a name="29653741"></a>European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. <i>J Hepatol</i>. 2018;69(2):406-460. doi:10.1016/j.jhep.2018.03.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/29653741/pubmed" id="29653741" target="_blank">29653741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17854593">
<a name="17854593"></a>Fernández J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. <i>Gastroenterology</i>. 2007;133(3):818-824. doi:10.1053/j.gastro.2007.06.065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/17854593/pubmed" id="17854593" target="_blank">17854593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17030175">
<a name="17030175"></a>Fernández J, Ruiz del Arbol L, Gómez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. <i>Gastroenterology</i>. 2006;131(4):1049-1056. doi:10.1053/j.gastro.2006.07.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/17030175/pubmed" id="17030175" target="_blank">17030175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2021c">
<a name="Hooton.2021c"></a>Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 20, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2021b">
<a name="Hooton.2021b"></a>Gupta K. Acute simple cystitis in adult males. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 11, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2021a">
<a name="Hooton.2021a"></a>Hooton TM, Kalpana G. Acute uncomplicated cystitis in women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 16, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1316075">
<a name="1316075"></a>Iravani A. Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated urinary tract infections in adults. <i>Am J Med</i>. 1992;92(4A):75S-81S. doi:10.1016/0002-9343(92)90314-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/1316075/pubmed" id="1316075" target="_blank">1316075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30213330">
<a name="30213330"></a>Lee CC, Lee MG, Hsieh R, et al. Oral fluoroquinolone and the risk of aortic dissection. <i>J Am Coll Cardiol</i>. 2018;72(12):1369-1378. doi:10.1016/j.jacc.2018.06.067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/30213330/pubmed" id="30213330" target="_blank">30213330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12220765">
<a name="12220765"></a>Lo WY, Friedman JM. Teratogenicity of Recently Introduced Medications in Human Pregnancy. <i>Obstet Gynecol</i>. 2002;100(3):465-473.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/12220765/pubmed" id="12220765" target="_blank">12220765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9624471">
<a name="9624471"></a>Loebstein R, Addis A, Ho E, et al, “Pregnancy Outcome Following Gestational Exposure to Fluoroquinolones: A Multicenter, Prospective Controlled Study,” <i>Antimicrob Agents Chemother</i>, 1998, 42(6):1336-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/9624471/pubmed" id="9624471" target="_blank">9624471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24612987">
<a name="24612987"></a>Lontos S, Shelton E, Angus PW, et al. A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients. <i>J Dig Dis</i>. 2014;15(5):260-267. doi:10.1111/1751-2980.12132<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/24612987/pubmed" id="24612987" target="_blank">24612987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19250986">
<a name="19250986"></a>Loomba R, Wesley R, Bain A, Csako G, Pucino F. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. <i>Clin Gastroenterol Hepatol</i>. 2009;7(4):487-493. doi:10.1016/j.cgh.2008.12.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/19250986/pubmed" id="19250986" target="_blank">19250986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32702756">
<a name="32702756"></a>Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. <i>Blood</i>. 2020;136(11):1225-1240. doi:10.1182/blood.2019000944<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/32702756/pubmed" id="32702756" target="_blank">32702756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8268363">
<a name="8268363"></a>Mattila L, Peltola H, Siitonen A, et al. Short-Term Treatment of Traveler's Diarrhea With Norfloxacin: A Double-Blind, Placebo-Controlled Study During Two Seasons. <i>Clin Infect Dis</i>. 1993;17(4):779-782.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/8268363/pubmed" id="8268363" target="_blank">8268363</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Norfloxacin [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; June 2019</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24841264">
<a name="24841264"></a>Padberg S, Wacker E, Meister R, et al. Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones. <i>Antimicrob Agents Chemother</i>. 2014;58(8):4392-4398.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/24841264/pubmed" id="24841264" target="_blank">24841264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PHAC.1">
<a name="PHAC.1"></a>Public Health Agency of Canada (PHAC). Gonorrhea guide: key information and resources. <a href="https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/gonorrhea/treatment-follow-up.html" target="_blank">https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/gonorrhea/treatment-follow-up.html</a>. Published November 9, 2021. Accessed September 14, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Runyon.1">
<a name="Runyon.1"></a>Runyon BA. Spontaneous bacterial peritonitis in adults: treatment and prophylaxis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1441044">
<a name="1441044"></a>Schaeffer AJ, Anderson RU. Efficacy and tolerability of norfloxacin vs. ciprofloxacin in complicated urinary tract infection. <i>Urology</i>. 1992;40(5):446-449. doi:10.1016/0090-4295(92)90461-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/1441044/pubmed" id="1441044" target="_blank">1441044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. <a href="http://www.fda.gov/Drugs/DrugSafety/ucm511530.htm" target="_blank">http://www.fda.gov/Drugs/DrugSafety/ucm511530.htm</a>. Published May 12, 2016. Accessed November 18, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9710 Version 286.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
